Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation
Authors
Keywords
-
Journal
ONCOGENE
Volume -, Issue -, Pages -
Publisher
Springer Nature America, Inc
Online
2018-11-02
DOI
10.1038/s41388-018-0537-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma
- (2017) Manish A. Shah et al. JAMA Oncology
- Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment
- (2016) Puyu Shi et al. CANCER LETTERS
- A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer
- (2016) Lee S. Rosen et al. CLINICAL CANCER RESEARCH
- Acid sphingomyelinase is required for cell surface presentation of Met receptor tyrosine kinase in cancer cells
- (2016) Linyu Zhu et al. JOURNAL OF CELL SCIENCE
- Preclinical Evaluation of AMG 337, a Highly Selective Small Molecule MET Inhibitor, in Hepatocellular Carcinoma
- (2016) Zhiqiang Du et al. MOLECULAR CANCER THERAPEUTICS
- Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody
- (2016) Simona Cignetto et al. Molecular Oncology
- A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction
- (2016) M. A. Shah et al. ONCOLOGIST
- Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer
- (2015) V. Diéras et al. ANNALS OF ONCOLOGY
- Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases
- (2015) Shunchao Yan et al. Diagnostic Pathology
- Predictive and prognostic value of de novo MET expression in patients with advanced non-small-cell lung cancer
- (2015) Anna Li et al. LUNG CANCER
- The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma
- (2015) Steven N. Steinway et al. PLoS One
- MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC)
- (2015) David Casadevall et al. Oncotarget
- Essential role of Her3 in two signaling transduction patterns: Her2/Her3 and MET/Her3 in proliferation of human gastric cancer
- (2014) Chen Yun et al. MOLECULAR CARCINOGENESIS
- Crosstalk Between Nuclear MET and SOX9/β-Catenin Correlates with Castration-Resistant Prostate Cancer
- (2014) Yingqiu Xie et al. MOLECULAR ENDOCRINOLOGY
- MET Gene Copy Number Predicts Worse Overall Survival in Patients with Non-Small Cell Lung Cancer (NSCLC); A Systematic Review and Meta-Analysis
- (2014) Anastasios Dimou et al. PLoS One
- How IGF-1 activates its receptor
- (2014) Jennifer M Kavran et al. eLife
- How insulin engages its primary binding site on the insulin receptor
- (2013) John G. Menting et al. NATURE
- Met degradation: more than one stone to shoot a receptor down
- (2012) Jonathan Lefebvre et al. FASEB JOURNAL
- c-Met function requires n-linked glycosylation modification of pro-Met
- (2012) Run Chen et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Differential roles of trans-phosphorylated EGFR, HER2, HER3 and RET as heterodimerisation partners of MET in lung cancer with MET amplification
- (2011) J Tanizaki et al. BRITISH JOURNAL OF CANCER
- Toward the Prognostic Significance and Therapeutic Potential of HER3 Receptor Tyrosine Kinase in Human Colon Cancer
- (2011) A. Beji et al. CLINICAL CANCER RESEARCH
- A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3
- (2011) X. Liu et al. CLINICAL CANCER RESEARCH
- Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks
- (2011) Yu Kataoka et al. INVESTIGATIONAL NEW DRUGS
- The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking
- (2011) P Mazot et al. ONCOGENE
- Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells
- (2009) S Agarwal et al. BRITISH JOURNAL OF CANCER
- The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma
- (2009) T. Y. Seiwert et al. CANCER RESEARCH
- Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment
- (2009) Natalia Jura et al. CELL
- The Aberrant Localization of Oncogenic Kit Tyrosine Kinase Receptor Mutants Is Reversed on Specific Inhibitory Treatment
- (2009) H. Bougherara et al. MOLECULAR CANCER RESEARCH
- Mislocalized Activation of Oncogenic RTKs Switches Downstream Signaling Outcomes
- (2009) Chunaram Choudhary et al. MOLECULAR CELL
- Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3
- (2009) N. Jura et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- KIT Mutations Induce Intracellular Retention and Activation of an Immature Form of the KIT Protein in Gastrointestinal Stromal Tumors
- (2008) S. Tabone-Eglinger et al. CLINICAL CANCER RESEARCH
- Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation
- (2008) Stéphanie Kermorgant et al. JOURNAL OF CELL BIOLOGY
- Signaling networks assembled by oncogenic EGFR and c-Met
- (2008) A. Guo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now